[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hospitalisation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hospitalisation":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":45},"100640645","phase-2-multicenter-phase-ii-trial-of-nricm102-combined-with-standard-therapy-in-pneumonia-100640645",false,"NCT07583992","Multicenter Phase II Trial of NRICM102 Combined With Standard Therapy in Pneumonia","Inclusion Criteria:\n\n1. Male or female subjects aged 18 to 85 years\n2. The subjects are diagnosed with community-acquired pneumonia (CAP) at the time of hospital admission and must meet all of the following criteria:\n\n   Chest X-ray showing new onset or persistent pulmonary infiltrate At least two of the following abnormal clinical or laboratory findings: (a) Cough, (b) Sputum production, (c) Fever (≥37.8℃) or hypothermia (\\\u003C35℃), (d) Auscultatory findings of rales or bronchial breath sounds, (e) White blood cell count greater than 10×10⁹\u002FL or less than 4×10⁹\u002FL\n3. Subjects requiring hospitalization and intravenous antibiotic therapy\n4. Subjects who have received standard antibiotic therapy for less than 24 hours after hospital admission\n5. Subjects who are able to take the investigational product orally\n6. Subjects who are able to understand and comply with all study procedures and provide written informed consent\n\nExclusion Criteria:\n\n1. Subjects who have received systemic antibiotic treatment within 72 hours prior to screening; routine antibiotics administered after hospital admission are not included in this restriction\n2. Subjects who have used oral traditional Chinese medicine (TCM) or traditional Chinese medicine preparations that may affect efficacy assessment within 7 days prior to hospital admission\n3. Subjects who have been hospitalized within 15 days prior to current admission\n4. Subjects with aspiration pneumonia\n5. Subjects requiring admission to the intensive care unit (ICU)\n6. Subjects requiring hemodialysis\n7. Subjects with any malignancy, except those who have completed curative treatment with no signs of recurrence for more than five years and require no further anticancer therapy (based on medical history)\n8. Subjects with human immunodeficiency virus (HIV) infection\n9. Subjects requiring long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), steroids, or other immunosuppressants\n10. Subjects requiring antiviral agents for COVID-19 infection or influenza\n11. Subjects must be on a stable dose of Omeprazole or Warfarin\n12. Subjects with alcohol or substance abuse, or other major organic diseases, such as chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, tuberculosis (TB), or significant heart, kidney, or other major organ dysfunction or failure (based on medical history)\n13. Female subjects who are pregnant, breastfeeding, or of childbearing potential, or those intending to become pregnant between the signing of the Informed Consent Form (ICF) and the final observation\u002Fstudy time point, or who are unwilling to use an appropriate method of contraception. Acceptable highly effective methods of contraception include:\n\n    1. Surgical sterilization (male or female), contraceptive implants, or intrauterine devices (IUDs).\n    2. Injectable contraceptives, oral contraceptives, contraceptive patches, or vaginal rings, used in combination with one barrier method.\\*\n    3. Combination of two barrier methods.\\* \\*Effective barrier methods include diaphragms, male or female condoms, contraceptive sponges, or spermicides (creams or gels containing spermicidal chemicals).\n14. Subjects deemed unsuitable for study participation by the investigator","ALL","18 Years","85 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this clinical trial is to learn if NRICM102 (a Traditional Chinese Medicine) works to treat community-acquired pneumonia (CAP) in adults when added to standard antibiotic therapy. It will also learn about the safety of NRICM102. The main questions it aims to answer are:\n\n1. Does NRICM102 help participants reach clinical stability faster compared to placebo?\n2. What medical problems do participants have when taking NRICM102?\n\nResearchers will compare NRICM102 to a placebo (a look-alike substance that contains no drug) to see if NRICM102 works as an add-on treatment for community-acquired pneumonia.\n\nParticipants will:\n\n1. Take NRICM102 or a placebo (2 sachets, 3 times daily) in addition to standard intravenous antibiotic treatment for 7 days\n2. Be hospitalized and visited by the study team on Day 1, Day 4, and Day 8 for vital sign monitoring, symptom assessments, laboratory tests, and chest X-ray examinations\n3. Be contacted by telephone on Day 30 to check if they were readmitted to the hospital after discharge",[26,27,28,29,30],"Mild to Moderate","Community-Acquired Pneumonia (CAP)","Antibiotic Therapy","Intravenous","Hospitalisation",[32,27,33],"NRICM102","National Research Institute of Chinese Medicine, Ministry of Health and Welfare","NOT_YET_RECRUITING","2026-05-07",{"date":37,"type":38},"2026-05-13","ACTUAL",{"date":40,"type":20},"2026-06",{"date":42,"type":20},"2027-11",{"name":33,"class":44},"OTHER_GOV",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":45},"100611239","protein-supplementation-during-dialysis-prosed-100611239","NCT07237997","Protein Supplementation During Dialysis (PROSED)","Re-examining Nutrition in Dialysis Patients: Nutritional Losses and the Role of Supplementation (Part 2).","PROSED","Inclusion Criteria:\n\n* Age ≥ 18 years (no upper age limit)\n* Patients receiving maintenance dialysis for ≥ three months\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Anticipated live donor kidney transplant and\u002For kidney recovery within the period of sample collection.\n* Anticipated change of dialysis modality within the period of sample collection\n* Severe malnutrition based on either:\n\n  * Renal 7-point Subjective Global Assessment (SGA) scores of 1-2\n  * Global Leadership Initiative Malnutrition (GLIM) Stage 2\n* Protein-losing enteropathy.\n* Persistent nephrotic syndrome with \\>3g\u002Fday urinary protein loss.\n* Active wounds or burns contributing to protein losses as judged by the investigator.\n* Current active acute inflammatory illness (likely to have catabolic effect in the opinion of the investigator).\n* Current malignancy based on recent (\\\u003C12 months) diagnosis and\u002For active treatment for malignancy and\u002For planned treatment for malignancy, excluding non-melanoma skin cancers.\n* Pregnancy (current or planned within duration of study) or breast feeding.\n* People with swallowing difficulties precluding safe ingestion (International Dysphagia Diet Standardization Initiative (IDDSI) level 0 thin fluid).\n* People receiving intradialytic parenteral nutrition or intra-peritoneal amino acids, or any other forms of artificial feeding\n* People prescribed levodopa\n* People who are receiving chronic glucocorticoid therapy (\\>10mg day prednisolone or equivalent for \\>7 days within preceding 90 days).\n* People who are consuming a protein dietary intake above 1.5g protein\u002Fkg\u002Fbody weight.\n* People who, in the opinion of the investigator, will be unable to comply with study protocol requirements.\n* People who are vegan or other religious based dietary restrictions which would prevent them taking the supplement.",{"count":55,"type":20},114,[57],"NA","When a patient has dialysis some nutrients are lost in the process. Nutritional losses include protein, trace elements (i.e. zinc, copper and selenium) and water-soluble vitamins (Vitamins C and B). These nutrients are essential for normal body function, including a good immune system and nutritional status. For example, on average the protein losses during a dialysis session (the process where the blood is cleaned via a machine and special fluid) is equal to 6g of protein\u002Fday (which is the equivalent of the amount of protein in 1 egg). Protein needs for the general population are 0.8g protein per kg of body weight. Because people on dialysis lose protein via the dialysis, it is thought that these people need to eat more protein. Currently, in clinical practice for people receiving dialysis, the guidelines are to aim for 1.1 -1.4g of protein per kg of body weight. However, the research is old and very weak.\n\nDialysis treatments have changed over the past 40 years, and the investigator does not know if the replacement of these nutritional losses is important to how well people do on dialysis and if they have any effect on survival. Previous research is mostly limited to haemodialysis (a type of dialysis that requires a machine which cleans the patients' blood via special filters) and peritoneal dialysis (this is a type of dialysis which happens via the patients' tummy). There is no research on the nutritional supplementation in home HD and nocturnal HD. Our research will investigate if a higher protein provision leads to a reduction is hospital admissions and improved outcomes in patients receiving dialysis.",[60,61,62,63,64,65,66,30,67,68],"Dialysis Patients","Dialysis","Protein Energy Wasting","Protein Intake","High Protein Dietary Intake","Diet","Diet Therapy","Muscle Mass and Strength","Muscle Mass","2025-11-14",{"date":71,"type":38},"2025-11-20",{"date":73,"type":20},"2026-01-05",{"date":75,"type":20},"2029-10-30",{"name":77,"class":78},"University of Nottingham","OTHER"]